Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia

NCT01788020 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

202

Enrollment

OTHER

Sponsor class

Conditions

Waldenström's Macroglobulinemia

Interventions

DRUG: Dexamethasone, Rituximab, Cyclophosphamide
DRUG: Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib

Sponsor

University of Ulm

Collaborators

[object Object]